Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study
Abstract Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) prof...
Main Authors: | M.-B. Jensen, C. B. Pedersen, M.-A. Misiakou, M.-L. M. Talman, L. Gibson, U. B. Tange, H. Kledal, I. Vejborg, N. Kroman, F. C. Nielsen, B. Ejlertsen, M. Rossing |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-023-00551-0 |
Similar Items
-
Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
by: Maria Rossing, et al.
Published: (2021-01-01) -
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
by: Jincong Q. Freeman, et al.
Published: (2023-05-01) -
Predictive multigenic scale. Analysis of own results in metastatic breast cancer
by: R. M. Paltuev, et al.
Published: (2023-06-01) -
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
by: Giuseppe Curigliano, et al.
Published: (2023-02-01) -
Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)